Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Common Equity (2022 - 2025)

Coya Therapeutics' Common Equity history spans 4 years, with the latest figure at $27.3 million for Q3 2025.

  • For Q3 2025, Common Equity fell 14.76% year-over-year to $27.3 million; the TTM value through Sep 2025 reached $27.3 million, down 14.76%, while the annual FY2024 figure was $39.6 million, 11.06% up from the prior year.
  • Common Equity for Q3 2025 was $27.3 million at Coya Therapeutics, down from $28.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $39.6 million in Q4 2024 and bottomed at -$8.4 million in Q4 2022.
  • The 4-year median for Common Equity is $27.3 million (2025), against an average of $19.3 million.
  • The largest annual shift saw Common Equity soared 1042.04% in 2023 before it fell 19.7% in 2025.
  • A 4-year view of Common Equity shows it stood at -$8.4 million in 2022, then surged by 524.56% to $35.6 million in 2023, then increased by 11.06% to $39.6 million in 2024, then tumbled by 31.06% to $27.3 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Common Equity are $27.3 million (Q3 2025), $28.3 million (Q2 2025), and $33.4 million (Q1 2025).